Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.

about

Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.

Item

http://www.wikidata.org/entity/Q48154447

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Monocytic myeloid-derived supp ...... tients treated with dasatinib.

@en

Monocytic myeloid-derived supp ...... tients treated with dasatinib.

@nl

type

Item

label

Monocytic myeloid-derived supp ...... tients treated with dasatinib.

@en

Monocytic myeloid-derived supp ...... tients treated with dasatinib.

@nl

prefLabel

Monocytic myeloid-derived supp ...... tients treated with dasatinib.

@en

Monocytic myeloid-derived supp ...... tients treated with dasatinib.

@nl

P1476

Monocytic myeloid-derived supp ...... tients treated with dasatinib.

@en

P2093

Alessandra Romano

http://www.w3.org/2001/XMLSchema#string

Francesco Di Raimondo

http://www.w3.org/2001/XMLSchema#string

Giuseppina Camiolo

http://www.w3.org/2001/XMLSchema#string

Marina Scalia

http://www.w3.org/2001/XMLSchema#string

Nunziatina L Parrinello

http://www.w3.org/2001/XMLSchema#string

Piera La Cava

http://www.w3.org/2001/XMLSchema#string

Roberto Avola

http://www.w3.org/2001/XMLSchema#string

P2860

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

The immunobiology of cancer immunosurveillance and immunoediting

Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes.

Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.

Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.

Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation

Myeloid derived suppressor cells in chronic myeloid leukemia.

Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.

Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL).

P304

1070-1080

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCMM.13326

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Fabio Stagno

Cesarina Giallongo

Giuseppe Alberto Palumbo

Daniele Tibullo

Giovanni Li Volti

P577

2017-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29218828

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

5783858

http://www.w3.org/2001/XMLSchema#string